Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Axatilimab in Healthy Japanese Male Participants: Results from a Phase 1, Randomized, Double-Blind, Dose-Escalation Study

Authors

Institutions

Publication Details

Journal
Clinical Drug Investigation
Published
2025-05-17
DOI
https://doi.org/10.1007/s40261-025-01438-7
Citations
1
Primary Topic
Immune Cell Function and Interaction
Type
article
Field-Weighted Citation Impact
0.80

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Axatilimab in Healthy Japanese Male Participants: Results from a Phase 1, Randomized, Double-Blind, Dose-Escalation Study

Miwa Haranaka, Kazumi Suzukawa, Michael A. Pratta, Yan‐ou Yang et al.
1 citations
Clinical Drug Investigation
Immune Cell Function and Interaction
0.80
article

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Axatilimab in Healthy Japanese Male Participants: Results from a Phase 1, Randomized, Double-Blind, Dose-Escalation Study

Miwa Haranaka, Kazumi Suzukawa, Michael A. Pratta, Yan‐ou Yang, Hongfei Li, Kenzo Kinami
article en
1 citations

Abstract

No abstract available for this paper.
Clinical Drug InvestigationVol. 45(6)
Quantitative BioSciences (US), SOUSEIKAI Global Clinical Research Center (JP), Incyte (United States) (US)
Incyte, Syndax Pharmaceuticals
Openalex Percentile: Top 28%
Immune Cell Function and Interaction
0.80
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.